Biopharmaceutical News and Research

RSS
ValitaCell joins Beckman Coulter Life Sciences

ValitaCell joins Beckman Coulter Life Sciences

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost enters multi-project drug target discovery collaboration with Roche

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Quality Control in Food and Beverage Production

Quality Control in Food and Beverage Production

New compound proves to be potent against more than 300 drug-resistant bacteria

New compound proves to be potent against more than 300 drug-resistant bacteria

Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery

Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

Cytokine-based cancer immunotherapy: current progress and future prospects

Cytokine-based cancer immunotherapy: current progress and future prospects

Novel technique could offer an improved route to drug discovery and development

Novel technique could offer an improved route to drug discovery and development

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

Misinformation clouds America’s most popular emergency contraception

Misinformation clouds America’s most popular emergency contraception

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

MD Anderson and National Resilience launch the Cell Therapy Manufacturing Center

MD Anderson and National Resilience launch the Cell Therapy Manufacturing Center

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Landmark $20 million gift received to establish Mount Sinai-Royalty Pharma Alliance for Health Equity Research

Landmark $20 million gift received to establish Mount Sinai-Royalty Pharma Alliance for Health Equity Research

New therapeutic approach for cardiac repair after a heart attack

New therapeutic approach for cardiac repair after a heart attack

Sphere Fluidics strengthens commercial team with three new senior hires

Sphere Fluidics strengthens commercial team with three new senior hires

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.